Loading...
XSHG603998
Market cap628mUSD
Dec 26, Last price  
10.56CNY
1D
0.19%
1Q
-3.39%
Jan 2017
-40.07%
IPO
75.12%
Name

Hunan Fangsheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603998 chart
P/E
24.53
P/S
2.81
EPS
0.43
Div Yield, %
3.81%
Shrs. gr., 5y
0.71%
Rev. gr., 5y
9.15%
Revenues
1.63b
-9.12%
262,675,477332,305,398400,261,848415,613,172468,558,594534,256,841720,769,3491,051,077,4191,093,753,9541,278,765,0361,566,972,7271,792,000,9251,628,542,252
Net income
187m
-34.64%
51,875,91366,113,59873,435,03880,992,59190,676,32469,755,60859,680,44372,993,93278,910,70263,793,54270,040,562285,853,227186,823,361
CFO
88m
-70.98%
65,163,35424,209,130122,966,36394,161,67090,574,912118,700,82916,002,674176,061,522162,578,284236,661,643185,626,591301,625,89187,537,942
Dividend
Jun 11, 20240.2 CNY/sh
Earnings
May 14, 2025

Profile

Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. It offers medicines in the form of tablets, capsules, and granules for cardiovascular and cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infectives. The company was founded in 2002 and is based in Changsha, China.
URL
http://www.fangsheng.com.cn
IPO date
Dec 05, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,628,542
-9.12%
1,792,001
14.36%
1,566,973
22.54%
Cost of revenue
1,431,559
1,452,963
1,277,413
Unusual Expense (Income)
NOPBT
196,983
339,038
289,559
NOPBT Margin
12.10%
18.92%
18.48%
Operating Taxes
23,714
49,873
20,870
Tax Rate
12.04%
14.71%
7.21%
NOPAT
173,268
289,165
268,689
Net income
186,823
-34.64%
285,853
308.13%
70,041
9.79%
Dividends
(174,410)
(103,952)
(25,766)
Dividend yield
3.58%
3.02%
0.88%
Proceeds from repurchase of equity
(1,892)
BB yield
0.04%
Debt
Debt current
309,194
230,853
467,850
Long-term debt
195,313
299,541
101,831
Deferred revenue
32,860
37,225
53,409
Other long-term liabilities
2,796
45,035
1
Net debt
38,007
(122,298)
116,882
Cash flow
Cash from operating activities
87,538
301,626
185,627
CAPEX
(218,776)
Cash from investing activities
(197,402)
Cash from financing activities
(91,547)
126,581
FCF
(36,786)
270,941
116,463
Balance
Cash
229,304
440,034
274,301
Long term investments
237,197
212,658
178,497
Excess cash
385,074
563,092
374,450
Stockholders' equity
1,286,248
1,356,264
1,171,712
Invested Capital
1,722,508
1,509,305
1,488,265
ROIC
10.72%
19.29%
19.10%
ROCE
9.20%
16.10%
15.32%
EV
Common stock shares outstanding
444,818
429,430
429,430
Price
10.96
36.83%
8.01
17.79%
6.80
13.52%
Market cap
4,875,200
41.73%
3,439,732
17.79%
2,920,122
13.52%
EV
5,043,839
3,435,254
3,144,604
EBITDA
271,196
417,336
367,919
EV/EBITDA
18.60
8.23
8.55
Interest
20,808
22,955
18,390
Interest/NOPBT
10.56%
6.77%
6.35%